7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 
      
    		                       
      cash flows from operating activities
    		                       
      net income
    		-126,502,000 -120,613,000 -106,449,000 -111,122,000 -109,119,000 -87,150,000 -75,319,000 -51,418,000 -58,662,000 -73,937,000 -59,432,000 -63,227,000 -47,928,000 -40,373,000 -47,171,000 -41,385,000 -37,703,000 -30,471,000 -28,158,000 -31,776,000 -20,789,000 -26,708,000 -20,551,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                       
      stock-based compensation
    		13,358,000 18,510,000 11,687,000 11,652,000 12,693,000 13,455,000 9,679,000 10,220,000 10,529,000 10,688,000 7,546,000 8,906,000 8,157,000 7,687,000 11,863,000 10,159,000 8,361,000 3,861,000 5,488,000 5,992,000 3,361,000 3,981,000  
      depreciation on property and equipment
    		105,000 107,000 109,000 99,000 89,000 80,000 64,000 58,000 56,000 53,000 54,000 49,000 46,000 44,000 39,000 33,000 28,000 26,000 22,000 19,000 14,000 10,000  
      non-cash lease expense
    		24,000 24,000 22,000 23,000 22,000 66,000 252,000 295,000 293,000 290,000 287,000 284,000 281,000 279,000 275,000 280,000 277,000 274,000 219,000     
      changes in operating assets and liabilities:
    		                       
      accounts receivable
    		-25,000 129,000 85,000 -197,000 417,000 2,927,000 -4,140,000 266,000 -561,000 -142,000 2,000 2,945,000 9,764,000 -947,000          
      prepaid expenses and other current assets
    		1,164,000 498,000 -15,210,000 -5,239,000 -4,692,000 -1,849,000 -8,518,000 2,836,000 -1,022,000 8,262,000 -6,236,000 -4,171,000 -925,000 -9,201,000 5,946,000 -7,830,000 982,000 3,039,000      
      other assets
    		167,000 -1,361,000 -195,000 530,000                    
      accounts payable
    		-1,065,000 -9,401,000 -2,304,000 -260,000 9,369,000 3,879,000 3,392,000 -3,704,000 -18,915,000 25,011,000 -12,629,000 6,472,000 6,518,000 -17,485,000 14,871,000 -427,000 1,135,000 675,000 337,000 -3,823,000 -2,074,000 6,811,000 -1,637,000 
      accrued expenses and other current liabilities
    		10,259,000 -5,304,000                      
      net cash from operating activities
    		-102,515,000 -117,411,000 -110,637,000 -100,391,000 -88,647,000 -76,199,000 -59,699,000 -47,098,000 -60,060,000 -47,370,000 -55,793,000 -46,395,000 -20,186,000 -65,819,000 -32,956,000 -31,895,000 -20,047,000 -21,214,000 -22,496,000 -22,815,000 -24,218,000 -13,798,000 -23,050,000 
      capex
    		0 0 0 -180,000 -196,000 -182,000 0 -131,000 -34,000 -45,000 0 -98,000 -31,000 -42,000 0 -74,000 -44,000 -18,000 0 -29,000 -39,000 -28,000 0 
      free cash flows
    		-102,515,000 -117,411,000 -110,637,000 -100,571,000 -88,843,000 -76,381,000 -59,699,000 -47,229,000 -60,094,000 -47,415,000 -55,793,000 -46,493,000 -20,217,000 -65,861,000 -32,956,000 -31,969,000 -20,091,000 -21,232,000 -22,496,000 -22,844,000 -24,257,000 -13,826,000 -23,050,000 
      cash flows from investing activities
    		                       
      purchase of property and equipment
    		   -180,000 -196,000 -182,000  -131,000 -34,000 -45,000  -98,000 -31,000 -42,000  -74,000 -44,000 -18,000  -29,000 -39,000 -47,000  
      net cash from investing activities
    		  -201,000 -180,000 -196,000 -182,000 -150,000 -131,000 -34,000 -45,000 -26,000 -98,000 -31,000 -42,000 -118,000 -74,000 -44,000 -18,000 -95,000 -29,000 -39,000 -47,000 -10,000 
      cash flows from financing activities
    		                       
      proceeds from stock options exercised
    		24,595,000 2,918,000 931,000 2,464,000 730,000 686,000 1,545,000 3,111,000 148,000 890,000 233,000 403,000 0 21,000     0 725,000 119,000 63,000  
      net cash from financing activities
    		24,595,000 2,918,000 450,612,000 2,464,000 730,000 686,000 1,545,000 469,844,000 148,000 890,000 233,000 70,631,000 0 21,000 0 0 200,038,000 91,000 763,000 446,000 188,350,000 193,553,000 101,000 
      effect of exchange rate changes on cash and cash equivalents
    		878,000 -566,000 -488,000 -149,000 1,049,000 335,000 2,732,000 -1,606,000 -86,000 -47,000 -490,000 2,697,000            
      net change in cash and cash equivalents
    		-77,042,000 -115,059,000 339,286,000 -98,256,000 -87,064,000 -75,360,000 -55,572,000 421,009,000 -60,032,000 -46,572,000 -56,076,000 26,835,000            
      cash and cash equivalents – beginning of period
    		0 713,971,000 0 0 0 635,365,000 0 0 0 376,532,000 0 0            
      cash and cash equivalents – end of period
    		-77,042,000 598,912,000 339,286,000 -98,256,000 -87,064,000 560,005,000 -55,572,000 421,009,000 -60,032,000 329,960,000 -56,076,000 26,835,000            
      supplemental disclosure of cash paid:
    		                       
      income taxes
    		  901,000 0               0 74,000    
      income tax receivable
    		                  -67,000 -441,000 -16,000 12,000 -36,000 
      accrued expenses
    		  1,647,000 4,146,000 10,668,000 -7,538,000 15,459,000 -5,343,000 8,527,000 -17,294,000 14,290,000 2,635,000 4,185,000 -5,542,000 -6,716,000 8,290,000 6,727,000 1,171,000 1,878,000 7,756,000 -4,569,000 -597,000 2,675,000 
      operating lease liabilities
    		  -23,000 -23,000 -23,000 -69,000 -258,000 -308,000 -305,000 -301,000 -292,000 -288,000 -284,000 -281,000    -360,000 -111,000 -544,000 -2,000 -141,000  
      due to roivant sciences ltd.
    		                      56,000 
      purchases of property and equipment
    		                       
      proceeds from issuance of common stock upon underwritten offering and private placement
    		                       
      payment of offering and private placement costs
    		      0                 
      non-cash operating activity
    		                       
      operating lease right-of-use assets obtained in exchange for operating lease liabilities
    		                       
      proceeds from issuance of common stock upon underwritten public offering and private placement
    		                       
      proceeds from issuance of common stock upon underwritten offering
    		          0             
      payment of offering costs
    		          0             
      proceeds from investment by roivant sciences ltd.
    		              0 0        
      capital contributions
    		              0 0 38,000 91,000 763,000 116,000 53,000 164,000 291,000 
      other non-cash items
    		                       
      effect of exchange rate changes on cash
    		             -772,000 -112,000         
      net change in cash
    		             -66,612,000 -33,186,000 -31,949,000 179,947,000 -21,141,000 -21,828,000 -22,398,000 164,093,000 179,708,000 -22,959,000 
      cash – beginning of period
    		             493,817,000 0 0 0 400,146,000 0 0 0 100,571,000 0 
      cash – end of period
    		             427,205,000 -33,186,000 -31,949,000 179,947,000 379,005,000 -21,828,000 -22,398,000 164,093,000 280,279,000 -22,959,000 
      preferred stock as converted
    		             10,000,000 0 0 0 10,000,000 0 0 0 10,000,000  
      options
    		             8,214,245,000  546,632,000 -555,245,000 6,712,189,000  -76,950,000 596,128,000 5,238,554,000  
      restricted stock units
    		             2,731,530,000 -865,945,000 142,712,000 2,462,174,000 931,923,000  87,780,000 0 127,200,000  
      total
    		             10,955,775,000 449,210,000 689,344,000 1,906,929,000 7,654,112,000 3,111,963,000 10,830,000 -10,303,872,000 16,275,754,000  
      proceeds from issuance of common stock upon underwritten public offering
    		                  0 0 188,753,000 131,030,000  
      proceeds from issuance of common stock upon warrant redemption
    		                  0 0 0 65,752,000  
      payment of deferred offering costs
    		                  0 -261,000 -373,000 -602,000  
      repayment of note payable to roivant sciences ltd.
    		                    -202,000 -2,854,000  
      stock options
    		                       
      operating lease and other noncurrent liabilities
    		               -275,000        
      foreign currency translation adjustments
    		                 571,000 -765,000 689,000 -232,000 26,000  
      restricted stock
    		                     900,000,000  
      earnout shares
    		                     10,000,000,000  
      loss on disposal of property and equipment
    		                      0 
      gain on extinguishment of convertible notes
    		                       
      write-off of deferred offering costs
    		                      0 
      prepaid expenses
    		                  -1,339,000 -1,119,000 -41,000 -353,000 -5,415,000 
      value-added tax receivable
    		                  0 0 0 3,009,000 -13,000 
      proceeds from notes payable to roivant sciences ltd.
    		                      0 
      repayment of convertible promissory note payable to roivant sciences ltd.
    		                      0 
      proceeds from convertible promissory notes
    		                       
      repayment of convertible promissory notes
    		                       
      settlement of common stock subscribed
    		                      0 
      recapitalization transaction
    		                      0 
      operating lease right-of-use assets obtained and exchanged for operating lease liabilities
    		                  32,000 259,000 -291,000 4,215,000  
      non-cash investing activity
    		                       
      payable for purchase of property and equipment
    		                       
      non-cash financing activity
    		                       
      conversion of convertible promissory notes to common stock
    		                      0 
      deferred offering costs in accrued expenses
    		                      -328,000 
      cancellation of interest on convertible promissory notes recorded in equity
    		                       
      total non-cash financing activity
    		                       
      warrants
    		                       
      gain on extinguishment of convertible notes payable
    		                       
      income tax payable
    		                       
      proceeds from convertible promissory notes payable
    		                       
      repayment of convertible promissory notes payable
    		                       
      noncash lease expense
    		                    279,000 152,000  
      other
    		                       
      proceeds from note payable to roivant sciences ltd.
    		                       
      purchase of property and equipment in accounts payable
    		                     19,000  
      non-cash investing and financing activities
    		                       
      net parent investment
    		                       
      proceeds from issuance of common stock
    		                       
      non-cash investing activities
    		                       
      non-cash financing activities
    		                       
      reclassification of net parent investment to accumulated deficit
    		                       
      common stock issuance costs in accrued expenses
    		                       
      cancelation of interest on convertible promissory notes recorded in equity
    		                       
      •
    		                       
      stock-based compensation expense
    		                       
      depreciation expense
    		                       
      unrealized currency translation adjustment
    		                       
      purchase of property and equipment in accounts payable and amounts due to roivant sciences ltd.
    		                       
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.